Biofarma Group
Biofarma Group is an Italian-headquartered CDMO producing nutraceuticals, medical devices, and active cosmetics for third-party brands across Italy, France, the US, and China, operating under private equity owner Ardian since 2023.
- Company typePrivate
- Founded2017
- HeadquartersMereto Di Tomba, Italy
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Biofarma Group does
Biofarma Group is an Italian-headquartered Contract Development and Manufacturing Organization (CDMO) that produces health nutrition products (nutraceuticals including probiotics and vitamins), medical devices, and active cosmetics for third-party brands. The group operates as Biofarma Srl, registered in Italy with its headquarters in Mereto di Tomba and additional manufacturing sites in Gallarate and San Pietro Viminario (Italy), Biofarma Group France, and following the 2023 acquisition of US Pharma Lab, operations in the United States and China. Biofarma delivers an integrated service stack spanning research and development, quality control laboratory, regulatory advice, contract production, packaging, logistics, and certification, enabling customers to source end-to-end development and manufacturing from a single partner. The company also generates revenue through out-licensing of proprietary products and technologies, including a patented electrospinning-based cosmetic patch platform and an advanced analytical method for lactose detection in food supplements and pharmaceutical products.
The company's revenue model is fundamentally B2B: long-term contract development and manufacturing engagements with enterprise customers in the nutraceutical, medical device, and cosmetics industries, supplemented by licensing royalties on proprietary out-licensed products. Pricing is not publicly disclosed and is quoted on a project basis. Go-to-market is enterprise field sales supported by participation in major industry trade shows (CPHI, SupplySide Global, Healthplex Expo, Nutriform Business Days) and content marketing through the 'Shaping the Future' corporate magazine. Biofarma is owned by private equity firm Ardian following a 2023 transaction that also involved the US Pharma Lab acquisition and reinvestment by current shareholders, making it a privately held, PE-backed industrial CDMO with no public listing.
Biofarma Group firmographics
Firmographics- Name
- Biofarma Group
- Legal name
- Biofarma Srl
- Website
- https://biofarmagroup.it
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Biofarma Group is an Italian-headquartered CDMO producing nutraceuticals, medical devices, and active cosmetics for third-party brands across Italy, France, the US, and China, operating under private equity owner Ardian since 2023.
- Ownership category
- akta.pro rank
Biofarma Group industry classification
Industry- Product category
- Contract Manufacturing Services (CDMO)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (33911), Scientific Research and Development Services (5417), Packaging and Labeling Services (561910)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Biofarma Group is headquartered
LocationHeadquarters
- HQ city
- Mereto Di Tomba
- HQ country
- Italy
- HQ region
- Europe
Offices6 records
Markets served
Biofarma Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Biofarma Group provides customized development and production of nutraceuticals (including probiotics and vitamins), medical devices, and active cosmetics for third-party companies. Revenue is generated through long-term B2B manufacturing contracts as a CDMO.
- Out-Licensing Production: The company also engages in out-licensing of proprietary products and technologies, generating additional revenue streams through licensing arrangements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Biofarma Group product offering
Product offeringCore offering
Biofarma Group is a Contract Development and Manufacturing Organization (CDMO) that produces, develops, and packages health nutrition products (nutraceuticals including probiotics and vitamins), medical devices, and active cosmetics for third-party brands. The company delivers integrated end-to-end services spanning R&D, quality control, regulatory advice, production, packaging, and logistics to enterprise customers across Europe, North America, and Asia.
Product overview
Biofarma Group operates as a Contract Development and Manufacturing Organization (CDMO) providing integrated manufacturing services for the nutraceutical, medical device, and cosmetic industries. The company's product portfolio consists of three main product lines: Health Nutrition (nutraceuticals including probiotics and vitamins), Medical Devices (ready-to-market devices), and Active Cosmetics. These products are supported by a comprehensive suite of services including Research & Development, Quality Control Laboratory, Regulatory Advice, Production, Packaging, and Logistics. Following the acquisition of US Pharma Lab in 2023, the group now operates manufacturing sites across Italy, France, the US, and China, establishing the world's first dedicated toll manufacturer in the nutraceutical industry.
Differentiator
Problem solved
Functional benefit
Products and services
- Health Nutrition Contract manufacturing of health nutrition products for third parties, including nutraceuticals such as probiotics and vitamins, capable of preventing chronic diseases and improving health status.
- Medical Devices Development and manufacturing of innovative, ready-to-market medical devices for third parties and out-licensing arrangements.
- Active Cosmetics Development and production of active cosmetic products for third parties, promoting environmental sustainability and new beauty concepts, including electrospinning-based skincare patches.
- Research & Development Services R&D laboratory services supporting product innovation and development for third-party nutraceutical, medical device, and cosmetics clients.
- Quality Control Laboratory Services Analytical and quality control laboratory services ensuring maximum quality, safety, and regulatory compliance for supplements and pharmaceutical products, including advanced lactose detection methods.
- Regulatory Advice Services Regulatory consulting and advisory services ensuring products comply with applicable regulations across target markets.
- Contract Production Services Contract manufacturing and production services for nutraceutical, medical device, and cosmetic products across facilities in Italy, France, the US, and China.
- Packaging Services Primary and secondary packaging services for nutraceutical, medical device, and cosmetic products.
- Logistics Services Distribution and logistics services for finished products manufactured under contract.
- Certification, Licenses and Policies Services Certification and licensing services ensuring compliance with industry standards and regulations for client products.
Quantifiable outcome
- First dedicated toll manufacturer in nutraceutical industry
- +1 more outcomes
Companies that use Biofarma Group
Customer profileSegments3 records
Ideal customer profiles3 records
Biofarma Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Biofarma Group partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- AIRC (Associazione Italiana per la Ricerca sul Cancro)minorBiofarma Group partners with AIRC in the fight against cancer, firmly supporting the Azalea Research Campaign. The company reaffirms its commitment as a 'Company Against Cancer,' with prevention as a daily choice and research as a promise for the future.
- US Pharma LabcoreBiofarma Group acquired 100% of US Pharma Lab, an American company specializing in customized development and production of nutraceuticals including probiotics and vitamins. This acquisition creates the world's first contract manufacturing organization dedicated solely to nutraceutical products with operations in the US, Europe, and China. The deal involved reinvestment by current shareholders.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Biofarma Group competitors and assessment
Company assessmentDirect peers
- Aenova Group: German-headquartered CDMO serving pharmaceutical and nutraceutical customers across multiple dosage forms. Most directly comparable to Biofarma as a European mid-market CDMO with a similar mix of contract manufacturing for pharma and consumer health brands.
- Recipharm: Swedish CDMO with multiple European manufacturing sites and PE ownership (EQT), comparable to Biofarma in scale, multi-site European footprint, and contract manufacturing for pharma and consumer health customers.
- NextPharma: European CDMO with sites across the UK, Germany, and Finland providing contract development and manufacturing for pharmaceutical and nutraceutical customers. Closely comparable in service mix (development, manufacturing, packaging) and customer segments.
- Alcami Corporation: US-headquartered CDMO offering contract development, manufacturing, and analytical services to pharma and consumer health clients. Comparable mid-market CDMO profile and service offering, though with US rather than European manufacturing base.
- Adare Pharma Solutions: US CDMO specializing in oral dose formulation and contract manufacturing for pharma and consumer health customers. Comparable in CDMO model and customer types, though with stronger US-centric exposure than Biofarma.
Broad incumbents
- Catalent: Large global pharma CDMO with broad capabilities across biologics, softgel, and oral dose manufacturing. Comparable in CDMO model and enterprise customer base but materially larger and broader in scope than Biofarma's nutraceutical focus.
- Lonza Group: Swiss-listed global CDMO leader serving pharma, biotech, and consumer health customers. Comparable as a contract manufacturing peer but operates at significantly larger scale and with greater biologics exposure than Biofarma.
- Thermo Fisher Scientific (Patheon): Diversified life sciences giant whose Patheon CDMO unit serves global pharma customers with contract manufacturing. Comparable as a CDMO peer but operates as part of a much larger platform with substantially broader capabilities than Biofarma.
Regional players
- Eurofarma: Latin American pharmaceutical company with vertically integrated manufacturing and CDMO activities. Comparable as a regional pharma/nutraceutical manufacturer but serves a different geography than Biofarma's Europe-US-China footprint.
Others
- dsm-firmenich: Global ingredients supplier for nutrition, health, and personal care with adjacent CDMO and contract manufacturing services. Comparable in serving nutrition and cosmetics customers but positioned upstream as an ingredient supplier rather than downstream contract manufacturer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Biofarma Group social profiles
Digital presenceBiofarma Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biofarma Group leadership team
Management profileNumber of profiles
Biofarma Group subsidiaries and ownership
Company hierarchySubsidiaries2 records
Biofarma Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biofarma Group M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biofarma Group
What does Biofarma Group do?
Biofarma Group is a Contract Development and Manufacturing Organization (CDMO) that produces, develops, and packages health nutrition products (nutraceuticals including probiotics and vitamins), medical devices, and active cosmetics for third-party brands. The company delivers integrated end-to-end services spanning R&D, quality control, regulatory advice, production, packaging, and logistics to enterprise customers across Europe, North America, and Asia.
Is Biofarma Group a public or private company?
Biofarma Group is a private company. It is classified as private equity controlled and is currently operating.
When was Biofarma Group founded?
Biofarma Group was founded in 2017. It employs 5,001 to 10,000 people.
Where is Biofarma Group based?
Biofarma Group is headquartered in Mereto Di Tomba, Italy, in the Europe region.
How does Biofarma Group make money?
Two revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are out-Licensing Production.
Who are Biofarma Group's main competitors?
Direct peers on record are Aenova Group, Recipharm, NextPharma, Alcami Corporation and Adare Pharma Solutions. Broad incumbents are Catalent, Lonza Group and Thermo Fisher Scientific (Patheon). Eurofarma is listed as a regional player. dsm-firmenich is listed as an others.
Does Biofarma Group have an API?
No public API is recorded for Biofarma Group.
What industry is Biofarma Group in?
Biofarma Group's product category is Contract Manufacturing Services (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 3254 and its SIC code is 2834.